Skip to main content
Journal cover image

Novel agents and regimens in acute myeloid leukemia: latest updates from 2022 ASH Annual Meeting.

Publication ,  Journal Article
DiNardo, KW; LeBlanc, TW; Chen, H
Published in: J Hematol Oncol
March 3, 2023

Developments in investigational agents and novel regimens in acute myeloid leukemia (AML) were reported in the 2022 American Society of Hematology (ASH) annual meeting. Encouraging efficacy data were presented from first-in-human studies of two investigational menin inhibitors, SNDX-5613 and KO-539, in relapsed and refractory (R/R) acute myeloid leukemia (AML) with KMT2A rearrangement or mutant NPM1, with overall response rates (ORR) of 53% (32/60) and 40% (8/20), respectively. The addition of the novel drug pivekimab sunirine, a first-in-class antibody-drug conjugate targeting CD123, to azacitidine and venetoclax in R/R AML resulted in an ORR of 45% (41/91), which rose to 53% in those who were venetoclax naïve. Additional novel triplet treatment combinations included the addition of magrolimab, an anti-CD47 antibody, to azacitidine and venetoclax, with an ORR of 81% (35/43) in newly diagnosed AML, including an ORR of 74% (20/27) in TP53 mutated AML. The addition of the FLT3 inhibitor gilteritinib to azacitidine/venetoclax was also featured, with an ORR of 100% (27/27) in newly diagnosed AML and an ORR of 70% (14/20) in R/R AML.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Hematol Oncol

DOI

EISSN

1756-8722

Publication Date

March 3, 2023

Volume

16

Issue

1

Start / End Page

17

Location

England

Related Subject Headings

  • Leukemia, Myeloid, Acute
  • Humans
  • Congresses as Topic
  • Azacitidine
  • 3211 Oncology and carcinogenesis
  • 3201 Cardiovascular medicine and haematology
  • 1112 Oncology and Carcinogenesis
  • 1102 Cardiorespiratory Medicine and Haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
DiNardo, K. W., LeBlanc, T. W., & Chen, H. (2023). Novel agents and regimens in acute myeloid leukemia: latest updates from 2022 ASH Annual Meeting. J Hematol Oncol, 16(1), 17. https://doi.org/10.1186/s13045-023-01411-x
DiNardo, Katherine W., Thomas W. LeBlanc, and Hui Chen. “Novel agents and regimens in acute myeloid leukemia: latest updates from 2022 ASH Annual Meeting.J Hematol Oncol 16, no. 1 (March 3, 2023): 17. https://doi.org/10.1186/s13045-023-01411-x.
DiNardo KW, LeBlanc TW, Chen H. Novel agents and regimens in acute myeloid leukemia: latest updates from 2022 ASH Annual Meeting. J Hematol Oncol. 2023 Mar 3;16(1):17.
DiNardo, Katherine W., et al. “Novel agents and regimens in acute myeloid leukemia: latest updates from 2022 ASH Annual Meeting.J Hematol Oncol, vol. 16, no. 1, Mar. 2023, p. 17. Pubmed, doi:10.1186/s13045-023-01411-x.
DiNardo KW, LeBlanc TW, Chen H. Novel agents and regimens in acute myeloid leukemia: latest updates from 2022 ASH Annual Meeting. J Hematol Oncol. 2023 Mar 3;16(1):17.
Journal cover image

Published In

J Hematol Oncol

DOI

EISSN

1756-8722

Publication Date

March 3, 2023

Volume

16

Issue

1

Start / End Page

17

Location

England

Related Subject Headings

  • Leukemia, Myeloid, Acute
  • Humans
  • Congresses as Topic
  • Azacitidine
  • 3211 Oncology and carcinogenesis
  • 3201 Cardiovascular medicine and haematology
  • 1112 Oncology and Carcinogenesis
  • 1102 Cardiorespiratory Medicine and Haematology